 |
|
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
Clin Mol Hepatol. 2023;29(4):987-1001. Published online 2023 Jul 5 DOI: https://doi.org/10.3350/cmh.2023.0035
|
|
Citations to this article as recorded by
 The Relationship Between Remnant Cholesterol and Visceral Adipose
Tissue: A National Cross-Sectional Study
Zhaoxiang Wang, Shao Zhong, Menghuan Wu, Xuejing Shao, Tian Gu, Mengjiao Xu, Qichao Yang
Hormone and Metabolic Research.2025; 57(01): 47. CrossRef Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases
Qi Zhong, Rui Zhou, Yi-Ning Huang, Rui-Dian Huang, Fu-Rong Li, Hao-Wen Chen, Yan-Fei Wei, Kuan Liu, Bi-Fei Cao, Kai-Yue Liao, Zheng-Yun Xu, Shi-Ao Wang, Xian-Bo Wu
Journal of Hepatology.2025; 82(3): 427. CrossRef Statin use and liver-related prognosis among patients with MASLD
Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
JHEP Reports.2025; 7(4): 101313. CrossRef Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
Jessica M. Rubino, Natalie Yanzi Ring, Krishna Patel, Xiaoqing Xia, Todd A. MacKenzie, Roberta M. diFlorio-Alexander
Biomedicines.2025; 13(1): 80. CrossRef Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
European Journal of Gastroenterology & Hepatology.2025; 37(5): 652. CrossRef A cross-sectional study of risk factors associated with sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease
Johnny Amer, Qusay Abdoh, Zaina Salous, Eithar Abu Alsoud, Sama AbuBaker, Ahmad Salhab, Manal Badrasawi
Frontiers in Medicine.2025;[Epub] CrossRef The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S
Hepatology International.2025; 19(2): 261. CrossRef Sarcopenia and non-alcoholic fatty liver disease - complex pathogenetic relationships
V. A. Akhmedov, V. S. Marinenko
Experimental and Clinical Gastroenterology.2025; (9): 110. CrossRef Effects of Pemafibrate on Serum Carnitine and Plasma Myostatin in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
Ryohei Tanigawa, Atsushi Nakajima, Yuichiro Eguchi, Hirokazu Takahashi, Rohit Loomba, Hideki Suganami, Masaya Tanahashi, Hidenori Arai
JCSM Communications.2025;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies
Parag Jain, Akanksha Jain, Rohitas Deshmukh, Pradeep Samal, Trilochan Satapathy, Ajazuddin
Clinics and Research in Hepatology and Gastroenterology.2025; 49(6): 102584. CrossRef Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis
Aikaterini Kamiliou, Vasileios Lekakis, Lampros Chrysavgis, Evangelos Cholongitas
Hepatology International.2024; 18(2): 688. CrossRef Prevalence of and Impact on the Outcome of Myosteatosis in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Aikaterini Kamiliou, Vasileios Lekakis, George Xynos, Evangelos Cholongitas
Cancers.2024; 16(5): 952. CrossRef Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
Alina M. Allen, Michael Charlton, Kenneth Cusi, Stephen A. Harrison, Kris V. Kowdley, Mazen Noureddin, Jay H. Shubrook
Postgraduate Medicine.2024; 136(3): 229. CrossRef Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
Piero Portincasa, Mohamad Khalil, Laura Mahdi, Valeria Perniola, Valeria Idone, Annarita Graziani, Gyorgy Baffy, Agostino Di Ciaula
International Journal of Molecular Sciences.2024; 25(11): 5640. CrossRef Association between metabolic dysfunction‐associated steatotic liver disease and myosteatosis measured by computed tomography
Myung Jin Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Woo Je Lee, Hong‐Kyu Kim, Chang Hee Jung
Journal of Cachexia, Sarcopenia and Muscle.2024; 15(5): 1942. CrossRef The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
Xiaoyan Li, Jie He, Qiuhua Sun
Clinical Nutrition.2024; 43(9): 2005. CrossRef Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c
Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
Clinical and Molecular Hepatology.2024; 30(4): 705. CrossRef Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
Cancers.2024; 16(18): 3161. CrossRef Diagnosis and management of metabolic dysfunction- associated steatotic liver disease in South Asians- A clinical review
Prajith Raj Ramesh, Priya Krishnan, Samyuktha Prabu, Varshini Srinivasan, Varalakshmi Niranjan
Obesity Pillars.2024; 12: 100142. CrossRef Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review
Basile Njei, Prince Ameyaw, Yazan Al-Ajlouni, Lea-Pearl Njei, Sarpong Boateng
Cureus.2024;[Epub] CrossRef Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clinical and Molecular Hepatology.2024; 30(4): 1039. CrossRef Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim
Clinical and Molecular Hepatology.2024; 30(4): 989. CrossRef AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B
Hyunjae Shin, Moon Haeng Hur, Byeong Geun Song, Soo Young Park, Gi-Ae Kim, Gwanghyeon Choi, Joon Yeul Nam, Minseok Albert Kim, Youngsu Park, Yunmi Ko, Jeayeon Park, Han Ah Lee, Sung Won Chung, Na Ryung Choi, Min Kyung Park, Yun Bin Lee, Dong Hyun Sinn, Se
Journal of Hepatology.2024;[Epub] CrossRef Correlation and predictive value of novel anthropometric indicators with adult sarcopenia and sarcopenia obesity
Xue Wu, Ziang Chen, Yuanhui Zhao, Hong Ren
Scientific Reports.2024;[Epub] CrossRef Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?
Catherine Stankevicius, Rachel H. Davis, Dep Huynh, Martine Hatzi, Stephanie Morgillo, Alice S. Day
Journal of Digestive Diseases.2024; 25(11-12): 645. CrossRef Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
Eugene Han, Yong-ho Lee
Clinical and Molecular Hepatology.2023; 29(4): 980. CrossRef Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
Baris Afsar, Rengin Elsurer Afsar
Clinical Nutrition.2023; 42(12): 2338. CrossRef Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah-Kheong Chan, Kee-Huat Chuah, Ruveena Bhavani Rajaram, Lee-Ling Lim, Jeyakantha Ratnasingam, Shireene Ratna Vethakkan
Journal of Obesity & Metabolic Syndrome.2023; 32(3): 197. CrossRef The newly proposed Metabolic Score for Visceral Fat is a reliable tool for identifying non-alcoholic fatty liver disease, requiring attention to age-specific effects in both sexes
Maobin Kuang, Jiajun Qiu, Dongdong Li, Chong Hu, Shuhua Zhang, Guotai Sheng, Yang Zou
Frontiers in Endocrinology.2023;[Epub] CrossRef
|